Catalent's book value per share for the quarter that ended in Mar. 2024 was $19.96.
During the past 12 months, Catalent's average Book Value Per Share Growth Rate was -23.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 12.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 27.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Catalent was 45.50% per year. The lowest was 12.80% per year. And the median was 31.75% per year.
Catalent's current price is $55.39. Its book value per share for the quarter that ended in Mar. 2024 was $19.96. Hence, today's PB Ratio of Catalent is 2.78.
During the past 13 years, the highest P/B Ratio of Catalent was 8.48. The lowest was 1.26. And the median was 4.95.
Catalent Book Value per Share Historical Data
The historical data trend for Catalent's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Catalent's Book Value per Share
For the Drug Manufacturers - Specialty & Generic subindustry, Catalent's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalent's PB Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Catalent's PB Ratio distribution charts can be found below:
* The bar in red indicates where Catalent's PB Ratio falls into.
Catalent Book Value per Share Calculation
Catalent's Book Value Per Share for the fiscal year that ended in Jun. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Catalent (NYSE:CTLT) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Catalent Book Value per Share Related Terms
Thank you for viewing the detailed overview of Catalent's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CTLT has been successfully added to your 